Acorda Therapeutics Shares Crushed After Receipt of FDA Refusal Letter

By Chris Lange Updated Jan 12, 8:41AM EST · Published Aug 29, 9:50AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Acorda Therapeutics Inc. (NASDAQ: ACOR) saw its shares get crushed early on Tuesday after the firm received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) in regards to its New Drug Application (NDA) for Inbrija.

Upon its preliminary review, FDA determined that the NDA, submitted back in June, was not sufficiently complete to permit a substantive review. The agency gave two reasons for the RTF. First was the date when the manufacturing site would be ready for inspection, And second was a question regarding the submission of the drug master production record.

The FDA also has requested additional information at resubmission, which was not part of the basis for the RTF.

Acorda is seeking immediate guidance, including a Type A meeting with the FDA, to respond to the issues.

[nativounit]

For some quick background: Inbrija is an investigational treatment for symptoms of off periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.

Ron Cohen, M.D., Acorda’s president and CEO, commented:

We will work with the FDA as quickly as possible to address the open issues and to clarify the path to successfully re-file our application. We remain confident in INBRIJA’s data package and its promise as an important new therapy for people with Parkinson’s disease. We see tremendous long-term value in its solid clinical profile, significant commercial opportunity and strong IP, and we remain focused on working to bring patients this important new therapy.

The stock was down about 29% at $18.22 in early trading indications Tuesday. The consensus analyst price target was $23.86, and a 52-week trading range is $13.60 to $33.00.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.